Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Last trade$59.57
Day change-$2.04 (-3.31%)
Day range$59.19 – $62.49
Volume500,660
Market cap$9.75B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$9.75B
Price / earnings
—
Price / book
3.92×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.09×
Profitability
Earnings per share
-$7.26
Return on assets
-38.42%
Return on equity
-46.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.04×
Current ratio
4.56×
Quick ratio
4.56×
Cash ratio
0.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$994.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PCVX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$37.95M
$34.93M
$33.07M
$32.22M
$32.45M
$32.04M
$32.66M
$28.56M
Research and development
$270.33M
$267.85M
$312.78M
$242.06M
$209.93M
$194.18M
$148.13M
$133.61M
Total operating expenses
$308.27M
$302.78M
$345.85M
$274.28M
$242.38M
$226.22M
$180.79M
$162.17M
Operating income
-$308.27M
-$302.78M
-$345.85M
-$274.28M
-$242.38M
-$226.22M
-$180.79M
-$162.17M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$297.06M
-$284.3M
-$320.62M
-$246.51M
-$212.83M
-$166.57M
-$140.72M
-$137.08M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$297.06M
-$284.3M
-$320.62M
-$246.51M
-$212.83M
-$166.57M
-$140.72M
-$137.08M
Net income attributable to common shareholders
-$297.06M
-$284.3M
-$320.62M
-$246.51M
-$212.83M
-$166.57M
-$140.72M
-$137.08M
EBITDA
-$302.5M
-$299.78M
-$342.9M
-$258.32M
-$239.32M
-$223.34M
-$177.84M
-$150.46M
Basic earnings per share
-$1.99
-$1.97
-$2.30
-$1.81
-$1.56
-$1.22
-$1.04
-$1.01
Diluted earnings per share
-$1.99
-$1.97
-$2.30
-$1.81
-$1.56
-$1.22
-$1.04
-$1.01
Recent news
Company coverage with links to the original publishers.
Vaxcyte (PCVX) has a mean analyst price target of $117.30, suggesting 87.4% upside potential from its current $62.61 price. The stock has gained 11.7% over the past four weeks. While price targets should be viewed skeptically, the stock benefits from strong analyst agreement on positive earnings estimate revisions and holds a Zacks Rank #2 (Buy) rating, indicating potential near-term upside.
Vaxcyte (PCVX) has gained 12.8% over the past four weeks and Wall Street analysts project a mean price target of $117.3, indicating a potential 75.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.
Vaxcyte, a clinical-stage vaccine company, announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds: 7.4 million shares of common stock at $64.00 per share and $500 million in convertible senior notes due 2032 with a 1.50% interest rate. The company plans to use net proceeds to fund clinical development of VAX-31 (31-valent pneumococcal conjugate vaccine) programs, manufacturing scale-up, commercial preparations for potential U.S. adult launch, and general corporate purposes. The offerings are expected to close on October 9, 2026.
Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.
The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.